natgillin/translations-raw huggingface dataset:
- de nye oplysninger om rofecoxib fra den kliniske undersøgelse APPROVe, der viste risiko
- the new data provided on rofecoxib by the APPROVe clinical study, which revealed a risk
Efter anmodning fra Europa-Kommissionen blev den igangværende undersøgelse af denne lægemiddelklasse udvidet til ud over de kardiovaskulære sikkerhedsaspekter også at omfatte alvorlige
Further to a request from the European Commission, the scope of the ongoing class review was broadened to include the assessment of serious skin reactions in addition to the cardiovascular safety
Disse oplysninger førte til, at indehaveren af markedsføringstilladelsen den 30. september 2004 trak Vioxx (rofecoxib) tilbage fra verdensmarkedet, og satte spørgsmålstegn ved den kardiovaskulære sikkerhed ved andre Cox-2hæmmere.
These data resulted in the worldwide withdrawal of Vioxx (rofecoxib) from the market on 30 September 2004 by the MAH and raised questions regarding the cardiovascular safety of other Cox-2 inhibitors.
I fortsættelse af drøftelserne på CHMP's plenarmøde i oktober 2004 henstillede EuropaKommissionen til, at dette folkesundhedsrelaterede spørgsmål, der vedrører alle aspekter af den kardiovaskulære sikkerhed, herunder thrombotiske hændelser og kardiorenale hændelser, indbringes for CHMP for at få det behandlet efter artikel 31 (”Referrals”) i direktiv 2001/83/EF, med senere ændringer, når det gælder decentralt godkendte produkter indeholdende celecoxib, etoricoxib og lumiracoxib, og underkastes en en gennemgang af CHMP i henhold til artikel 18 i Rådets forordning (EF) nr. 2309/93, med senere ændringer, når det gælder de centralt godkendte produkter indeholdende celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) og valdecoxib (Bextra/Valdyn), hvilket blev
Further to discussions at the CHMP October 2004 plenary meeting, the European Commission recommended that this public health issue on all aspects of cardiovascular safety including thrombotic events and cardio-renal events is the subject of Community referrals under Article 31 of Directive 2001/83/EC, as amended regarding decentrally authorised products containing celecoxib, etoricoxib and lumiracoxib and subject to a review procedure under Article 18 of Council Regulation (EEC) No 2309/93, as amended regarding the centrally authorised products containing celecoxib (Onsenal), parecoxib (Dynastat/Rayzon) and valdecoxib (Bextra/Valdyn), which were started in November 2004.
Den 20. april 2005 fremlagde Pfizer under en høring oplysninger om alvorlige hudreaktioner i
On 20 April 2005, Pfizer presented data on serious skin reactions for valdecoxib during a hearing.
Den 7. april 2005 anmodede Food and Drug Administration og EMEA Pfizer om frivilligt at trække Bextra (valdecoxib) tilbage fra markedet, og Pfizer indvilligede i at indstille salget og markedsføringen af Bextra på verdensplan, mens man afventede de videre drøftelser af det ugunstige risk/benefitforhold på grundlag af oplysningerne om alvorlige hudreaktioner.
On 7 April 2005, the FDA (Food and Drug Administration) and the EMEA requested that Pfizer voluntarily withdraw Bextra (valdecoxib) from the market and Pfizer agreed to suspend sale and marketing of Bextra worldwide pending further discussions on the unfavorable risk versus benefit due
I september 2004 underrettede indehaveren af markedsføringstilladelsen for rofecoxib (en selektiv Cox-2-hæmmer) EMEA om, at oplysninger fra en ny klinisk undersøgelse (APPROVe) af rofecoxib havde vist risiko for thrombotiske kardiovaskulære hændelser.
In September 2004, the Marketing Authorisation Holder (MAH) of rofecoxib (a selective Cox-2inhibitor) informed the EMEA that new clinical trial (APPROVe) data for rofecoxib have revealed a risk of thrombotic cardiovascular (CV) events.
- oplysningerne om celecoxib i APC-undersøgelsen, som tydede på en dosisrelateret øget
- the data on celecoxib presented in the APC study, which suggested a dose-related
Der var i CHMP enighed om, at det var nødvendigt at iværksætte en Urgent Safety Restriction vedrørende kardiovaskulære sikkerhed, med indførelse af nye kontraindikationer og skærpede advarsler og oplysninger om bivirkninger i produktresuméet og indlægssedlen.
The CHMP agreed that an Urgent Safety Restriction (USR) on cardiovascular safety was needed to introduce new contraindications and strengthen warnings and information on side effects in the SPC and the Package Leaflet (PL).
efter vurdering af oplysningerne om alvorlige hudreaktioner forbindes celecoxib med meget sjældne tilfælde af alvorlige hudreaktioner som er påvist i kliniske undersøgelser og overvågningen efter markedsføringen - analysen viser flere risikofaktorer for forekomst af disse alvorlige hudreaktioner i forbindelse med celecoxib.
Further to the assessment of the data on serious skin reactions, celecoxib is associated with very rare occurrence of serious skin reactions, as evidenced in clinical studies and postmarketing surveillance, which analysis revealed several risk factors for the occurrence of these serious skin reactions with celecoxib.
- tilføjelse af en advarsel til patienter med tidligere lægemiddelallergi af enhver art, - skærpelse af en advarsel for at fremhæve, at der nu med celecoxib er forekommet alvorlige
- Addition of a warning for patients with a history of any drug allergy, - Strengthening of a warning to highlight that fatal serious skin reactions have now occurred
- er af den opfattelse, at benefit/risk-forholdet for Onsenal til familiær adenomatøs polypose (FAP) fortsat er gunstigt, og at markedsføringstilladelserne bør opretholdes i overensstemmelse med det reviderede produktresumé og indlægssedlen (vedlagt i henholdsvis
- is of the Opinion that the benefit/risk balance of Onsenal in Familial Adenomatous Polyposis (FAP) remains favourable and the Marketing Authorisations should be maintained according to revised Summaries of Product Characteristics and Package Leaflet (attached in Annex I and IIIB, respectively of the CHMP Opinion), - concluded that the cardiovascular safety and serious skin reactions should be continuously and
Urgent Safety Restriction-proceduren blev påbebyndt den 16. februar 2005 og afsluttet den 17. februar 2005.
This USR was initiated on 16 February 2005 and finalised on
- tilføjelse af en advarsel til patienter med risikofaktorer for hjertesygdom som f.eks. hypertension, hyperlipidæmi (højt kolesterolniveau), diabetes og rygning, - tilføjelse af en advarsel til ordinerende læger om at overveje afbrydelse af behandlingen, hvis patienten under behandlingen oplever en forværring af et hvilket som helst af de beskrevne
- Addition of a warning for patients with risk factors for heart disease, such as hypertension, hyperlipidaemia (high cholesterol levels), diabetes and smoking, - Addition of a warning for prescribers to consider discontinuation of therapy if during treatment, patients deteriorate in any of the organ system functions described, - Addition of a warning for prescribers to exercise caution when prescribing NSAIDs, including celecoxib, in combination with ACE inhibitors or angiotensin II receptor antagonists,
- oplysningerne om lumiracoxib i Target-undersøgelsen, som tyder på en lidt større forekomst af thrombotiske hændelser (navnlig myokardieinfarkt) i forhold til naproxen, at alle foreliggende oplysninger viser øget risiko for kardiovaskulære bivirkninger ved Cox-2hæmmere som lægemiddelklasse, og der var i udvalget enighed om, at der er sammenhæng mellemdoseringens varighed og størrelse og sandsynligheden for en kardiovaskulær reaktion.
- the data on etoricoxib in the EDGE study and pooled analyses of other clinical trials, which suggested an association with a higher thrombotic risk than naproxen, - the data on lumiracoxib in the Target study, which suggested a small increase in thrombotic events (especially myocardial infarction) versus naproxen, all available data show an increased risk of CV adverse reactions for Cox-2 inhibitors as a class and agreed that there is an association between duration and dose of intake and the probability of suffering a CV reaction.
- konkluderede, at den kardiovaskulære sikkerhed og de alvorlige hudreaktioner løbende skal overvåges nøje og vurderes, - anbefaler opfølgningsforanstaltninger til videre undersøgelse af sikkerheden af celecoxib.
- recommended follow up measures to further investigate the safety of celecoxib.
- tilføjelse af kortfattet information om de kardiovaskulære resultater i PreSAP- (sikkerhed og virkning af celecoxib (SC-58635) ved forebyggelse af sporadiske adenomatøse kolorektale polypper) og APC-undersøgelserne (forebyggelse af sporadiske adenomatøse kolorektale polypper med celecoxib) med henblik på at indføje en strengere ordlyd vedrørende de
The changes of the Product Information related to the CV can be summarised as follows: - Addition of the contraindications Established ischaemic heart disease and/or cerebrovascular disease and Peripheral arterial disease, - Addition of brief information of the CV findings in PreSAP (Efficacy and safety of celecoxib (SC-58635) in the prevention of colorectal sporadic adenomatous polyps) and APC (Prevention of sporadic colorectal adenomas with celecoxib); to include more stringent
- oplysningerne om valdecoxib og parecoxib i CABG- (koronararterie-bypass transplantation) og CABG II-undersøgelserne, der viste en højere forekomst af alvorlige kardiovaskulære thromboemboliske hændelser i parecoxib/valdecoxib-behandlingsformen sammenlignet med patienter, der får placebo, - oplysningerne om etoricoxib i EDGE-undersøgelsen og i samlede analyser af andre kliniske undersøgelser, som tyder på, at den tilknyttede thromboserisiko er højere end for naproxen,
- the data on valdecoxib and parecoxib presented in the CABG (Coronary Artery Bypass Graft) and in the CABG II studies, which showed a higher rate of serious CV thromboembolic events in the parecoxib/valdecoxib treatment arm compared to the group
Pulver: 5 mg Solvens: 1,5
Powder: 5 mg Solvent: 1.5 ml
1 hætteglas + 1 fyldt injektionssprøjte r l
1 vial + 1 pre-filled syringe l t o r
Pulver: hætteglas (glas) Solvens: fyldt injektionssprøjte (glas)
Powder: vial (glass) Solvent: pre-filled syringe (glass)
Valtropin 5 mg/1,5 ml Pulver og solvens til injektionsvæske, opløsning (flergangsbrug)
EU/1/06/335/001 Valtropin 15 mg/1.5 ml Powder and solvent for solution for injection (multi-use)
Lægemiddelform
Strength Pharmaceutical Form Route of administration
Suspension til injektion
Suspension For Injection
Gastro-resistent tablet
Gastro-Resistant Tablet
Sublingual tablet Sublingual anvendelse
Sublingual Tablet Sublingual Use
Nasal anvendelse
Nasal Use
Oral pulver
Oral Powder
Oral suspension Sublingual anvendelse
Oral Suspension Sublingual Use
Intramuskulær anvendelse $ subkutan anvendelse
Intramuscular Use $
Filmovertrukket tablet
Film-Coated Tablet
Granulat til oral suspension
Granules For Oral Suspension
Orale dråber, suspension
Oral Drops, Suspension
Pulver til oral suspension
Powder For Oral Suspension
Grækenland Gap S.A.
Gap S.A.
Bakteriel lysat 3 mg tablet
Bacterial Lysate 3mg Tablet
Streptococcus Agalactiae 1000 mega enheder tablet, Haemophilus Influenzae 1500 mega enheder tablet, Staphylococcus Aureus 1000 mega enheder tablet, Streptococcus Pneumoniae 1000 mega enheder tablet
Streptococcus Agalactiae 1000 Mega Units Tablet, Haemophilus Influenzae 1500 Mega Units Tablet, Staphylococcus Aureus 1000 Mega Units Tablet, Streptococcus Pneumoniae 1000 Mega Units Tablet
Lysatum Bakteriale Mixtum 3 mg tablet
Lysatum Bacteriale Mixtum 3mg Tablet
Næsedråber, suspension
Nasal Drops, Suspension
Grækenland Rafarm Sa.
Rafarm Sa.
Streptococcus Agalactiae 1 giga enheder tablet, Haemophilus Influenzae 1,5 giga enheder tablet, Staphylococcus Aureus 1 giga enheder tablet, Streptococcus Pneumoniae 1 giga enheder tablet
Streptococcus Agalactiae 1 Giga Units Tablet, Haemophilus Influenzae 1.5 Giga Units Tablet, Staphylococcus Aureus 1 Giga Units Tablet, Streptococcus Pneumoniae 1 Giga Units Tablet
Lyofiliserede bakterielle lysater 7 mg tablet
Lyophilized Bacterial Lysates 7mg Tablet
Haemophilus Influenzae Type B (Hib) 1,25 gigaceller / 50 mg, Branhamella Catarrhalis Lysat 1,25 gigaceller / 50 mg, Klebsiella Pneumoniae (inaktiveret) 1,25 gigaceller / 50 mg, Staphylococcus Aureus inaktiverede bakterier 1,25 gigaceller / 50 mg, Streptococcus Pneumoniae inaktiverede bakterier 1,25 gigaceller / 50 mg, Streptococcus Pyogenes inaktiverede bakterier 1,25 gigaceller / 50 mg
Haemophilus Influenzae Type B (Hib) 1.25 Giga Cells / 50mg, Branhamella Catarrhalis Lysate 1.25 Giga Cells / 50mg, Klebsiella Pneumoniae (Inactivated) 1.25 Giga Cells / 50mg, Staphylococcus Aureus Inactivated Bacteria 1.25 Giga Cells / 50mg, Streptococcus Pneumoniae Inactivated Bacteria 1.25 Giga Cells / 50mg, Streptococcus Pyogenes Inactivated Bacteria 1.25 Giga Cells / 50mg
Haemophilus Influenzae Type B (Hib) 0,625 gigaceller / 25 mg, Branhamella Catarrhalis Lysat 0,625 gigaceller / 25 mg, Klebsiella Pneumoniae (inaktiveret) 0,625 gigaceller / 25 mg, Staphylococcus Aureus inaktiverede bakterier 0,625 gigaceller / 25mg, Streptococcus Pneumoniae inaktiverede bakterier 0,625 gigaceller / 25 mg, Streptococcus Pyogenes inaktiverede bakterier 0,625 gigaceller / 25 mg
Haemophilus Influenzae Type B (Hib) 0.625 Giga Cells / 25mg, Branhamella Catarrhalis Lysate 0.625 Giga Cells / 25mg, Klebsiella Pneumoniae (Inactivated) 0.625 Giga Cells / 25mg, Staphylococcus Aureus Inactivated Bacteria 0.625 Giga Cells / 25mg, Streptococcus Pneumoniae Inactivated Bacteria 0.625 Giga Cells / 25mg, Streptococcus Pyogenes Inactivated Bacteria 0.625 Giga Cells / 25mg
Bakteriel Lysat 7 mg kapsel
Bacterial Lysate 7mg Capsule
Bakteriel Lysat 3,5 mg kapsel
Bacterial Lysate 3.5mg Capsule
Broncho-Vaxom til voksne
Broncho-Vaxom Für Erwachsene
Lysatum Bakteriale Mixtum 7 mg kapsel
Lysatum Bacteriale Mixtum 7mg Capsule
Lysatum Bakteriale Mixtum 3,5 mg kapsel
Lysatum Bacteriale Mixtum 3.5mg Capsule
Broncho-Vaxom til børn
Broncho-Vaxom Für Kinder
Escherichia Coli (inaktiveret) 20 megaceller / Ml, Klebsiella Pneumoniae (inaktiveret) 10 megaceller / Ml, Staphylococcus Aureus Inaktiverede Bakterier 50 megaceller / Ml, Staphylococcus Epidermidis inaktiverede bakterier 50 megaceller / Ml Streptococcus Salivarius inaktiverede bakterier 10 megaceller / Ml, Streptococcus Pneumoniae inaktiverede bakterier 10 megaceller / Ml, Streptococcus Pyogenes inaktiverede bakterier 10 megaceller / Ml, Haemophilus Influenzae inaktiverede bakterier 10 megaceller / Ml, Corynebacterium Pseudodiphtheriticum inaktiverede bakterier 20 megaceller / Ml, Moraxella Catarrhalis inaktiverede bakterier 10 megaceller / MI
Escherichia Coli (Inactivated) 20 Mega Cells / Ml, Klebsiella Pneumoniae (Inactivated) 10 Mega Cells / Ml, Staphylococcus Aureus Inactivated Bacteria 50 Mega Cells / Ml, Staphylococcus Epidermidis Inactivated Bacteria 50 Mega Cells / Ml, Streptococcus Salivarius Inactivated Bacteria 10 Mega Cells / Ml, Streptococcus Pneumoniae Inactivated Bacteria 10 Mega Cells / Ml, Streptococcus Pyogenes Inactivated Bacteria 10 Mega Cells / Ml, Haemophilus Influenzae Inactivated Bacteria 10 Mega Cells / Ml, Corynebacterium Pseudodiphtheriticum Inactivated Bacteria 20 Mega Cells / Ml, Moraxella Catarrhalis Inactivated Bacteria 10 Mega Cells / Ml
Proteoglycaner af Klebsiella Pneumoniae 1,125 mg pose, Ribosomale Fraktioner (Ribosomer med en titer på 70% Rna) 0,75 mg pose, Ribosomer af Haemophilus Influenzae 5 enheder pose, Ribosomer af Streptococcus Pneumoniae 30 enheder pose, Ribosomale Fraktioner af Klebsiella Pneumoniae 35 enheder pose, Ribosomer fra Streptococcus Pyogenes gruppe A 30 enheder pose
Proteoglycanes Of Klebsiella Pneumoniae 1.125mg Sachet, Ribosomal Fractions (Ribosomes With A Titre Of 70% Rna) 0.75mg Sachet, Ribosomes Of Haemophilus Influenzae 5 Units Sachet, Ribosomes Of Streptococcus Pneumoniae 30 Units Sachet, Ribosomal Fractions Of Klebsiella Pneumoniae 35 Units Sachet, Ribosomes From Streptococcus Pyogenes Group A 30 Units Sachet
Broncho-Vaxom Lysatum Bakteriale Mixtum 7 mg kapsel
Broncho-Vaxom Lysatum Bacteriale Mixtum 7mg Capsule
Frysetørret (lyofiliseret), standardiseret bakteriel lysat 7 mg kapsel
Freeze-Dried (Lyophilised), Standardised Bacterial Lysate 7mg Capsule
Granulat til oral opløsning
Granules For Oral Solution
Escherichia Coli (inaktiveret) 2 megaceller / Ml, Klebsiella Pneumoniae (inaktiveret) 1 megaceller / Ml, Staphylococcus Aureus Inaktiverede Bakterier 5 megaceller / Ml, Staphylococcus Epidermidis inaktiverede bakterier 5 megaceller / Ml Streptococcus Salivarius inaktiverede bakterier 1 megaceller / Ml, Streptococcus Pneumoniae inaktiverede bakterier 1 megaceller / Ml, Streptococcus Pyogenes inaktiverede bakterier 1 megaceller / Ml, Haemophilus Influenzae inaktiverede bakterier 1 megaceller / Ml, Corynebacterium Pseudodiphtheriticum inaktiverede bakterier 2 megaceller / Ml, Moraxella Catarrhalis inaktiverede bakterier 1 megaceller / MI
Escherichia Coli (Inactivated) 2 Mega Cells / Ml, Klebsiella Pneumoniae (Inactivated) 1 Mega Cells / Ml, Staphylococcus Aureus Inactivated Bacteria 5 Mega Cells / Ml, Staphylococcus Epidermidis Inactivated Bacteria 5 Mega Cells / Ml, Streptococcus Salivarius Inactivated Bacteria 1 Mega Cells / Ml, Streptococcus Pneumoniae Inactivated Bacteria 1 Mega Cells / Ml, Streptococcus Pyogenes Inactivated Bacteria 1 Mega Cells / Ml, Haemophilus Influenzae Inactivated Bacteria 1 Mega Cells / Ml, Corynebacterium Pseudodiphtheriticum Inactivated Bacteria 2 Mega Cells / Ml, Moraxella Catarrhalis Inactivated Bacteria 1 Mega Cells / Ml
Escherichia Coli (inaktiveret) 200 megaceller / Ml, Klebsiella Pneumoniae (inaktiveret) 100 megaceller / Ml, Staphylococcus Aureus Inaktiverede Bakterier 500 megaceller / Ml, Staphylococcus Epidermidis inaktiverede bakterier 500 megaceller / Ml Streptococcus Salivarius inaktiverede bakterier 100 megaceller / Ml, Streptococcus Pneumoniae inaktiverede bakterier 100 megaceller / Ml, Streptococcus Pyogenes inaktiverede bakterier 100 megaceller / Ml, Haemophilus Influenzae inaktiverede bakterier 100 megaceller / Ml, Corynebacterium Pseudodiphtheriticum inaktiverede bakterier 200 megaceller / Ml, Moraxella Catarrhalis inaktiverede bakterier 100 megaceller / MI
Escherichia Coli (Inactivated) 200 Mega Cells / Ml, Klebsiella Pneumoniae (Inactivated) 100 Mega Cells / Ml, Staphylococcus Aureus Inactivated Bacteria 500 Mega Cells / Ml, Staphylococcus Epidermidis Inactivated Bacteria 500 Mega Cells / Ml, Streptococcus Salivarius Inactivated Bacteria 100 Mega Cells / Ml, Streptococcus Pneumoniae Inactivated Bacteria 100 Mega Cells / Ml, Streptococcus Pyogenes Inactivated Bacteria 100 Mega Cells / Ml, Haemophilus Influenzae Inactivated Bacteria 100 Mega Cells / Ml, Corynebacterium Pseudodiphtheriticum Inactivated Bacteria 200 Mega Cells / Ml, Moraxella Catarrhalis Inactivated Bacteria 100 Mega Cells / Ml
Standardiseret Lyophylisat af bakterielle lysater 7 mg kapsel
Standardized Lyophylisate Of Bacterial Lysates 7mg Capsule
Frysetørret (lyofiliseret), standardiseret bakteriel lysat 3,5 mg kapsel
Freeze-Dried (Lyophilised), Standardised Bacterial Lysate 3.5mg Capsule
Standardiseret Lyophylisat af bakterielle lysater 3,5 mg kapsel
Standardized Lyophylisate Of Bacterial Lysates 3.5mg Capsule
Lyofiliserede bakterielle lysater 7 mg kapsel
Lyophilized Bacterial Lysates 7mg Capsule
Broncho-Vaxom Lyofiliseret, standardiseret bakterieekstrakt 3,5 mg kapsel
Broncho-Vaxom Lyophilised, Standardised Bacterial Extract 3.5mg Capsule
Broncho-Vaxom Lyofiliserede bakterielle lysater 3,5 mg kapsel
Broncho-Vaxom Lyophilized Bacterial Lysates 3.5mg Capsule
Lyofiliseret, standardiseret bakterieekstrakt 7 mg kapsel
Lyophilised, Standardised Bacterial Extract 7mg Capsule
Lyofiliserede bakterielle lysater 3,5 mg kapsel
Lyophilized Bacterial Lysates 3.5mg Capsule
Broncho Vaxom Lyofiliserede bakterielle lysater 7 mg kapsel
Broncho Vaxom Lyophilized Bacterial Lysates 7mg Capsule
Membraner Fraktioner af Klebsiella Pneumoniae 15 enheder / Ml, Ribosomer af Haemophilus Influenzae 0,5 enheder / Ml, Ribosomer af Streptococcus Pneumoniae 3 enheder / Ml, Ribosomale Fraktioner af Klebsiella Pneumoniae 3,5 enheder / Ml, Ribosomer fra Streptococcus Pyogenes Gruppe A 3 enheder / Ml
Membranes Fractions Of Klebsiella Pneumoniae 15 Units / Ml, Ribosomes Of Haemophilus Influenzae 0.5 Units / Ml, Ribosomes Of Streptococcus Pneumoniae 3 Units / Ml, Ribosomal Fractions Of Klebsiella Pneumoniae 3.5 Units / Ml, Ribosomes From Streptococcus Pyogenes Group A 3 Units / Ml
Glycine 43 mg tablet, Haemophilus Influenzae Type B (Hib) 6 giga organismer tablet, Klebsiella Ozaenae 6 giga organismer tablet, Klebsiella Pneumoniae 6 giga organismer tablet, Neisseria Catarrhalis 6 giga organismer tablet, Staphylococcus Aureus 6 giga organismer tablet, Streptococcus Pneumoniae 6 giga organismer tablet, Streptococcus Pyogenes 6 giga organismer tablet, Streptococcus Viridans 6 giga organismer tablet, Lyofiliserede Bakterielle Lysater 50 mg tablet
Glycine 43mg Tablet, Haemophilus Influenzae Type B (Hib) 6 Giga Organisms Tablet, Klebsiella Ozaenae 6 Giga Organisms Tablet, Klebsiella Pneumoniae 6 Giga Organisms Tablet, Neisseria Catarrhalis 6 Giga Organisms Tablet, Staphylococcus Aureus 6 Giga Organisms Tablet, Streptococcus Pneumoniae 6 Giga Organisms Tablet, Streptococcus Pyogenes 6 Giga Organisms Tablet, Streptococcus Viridans 6 Giga Organisms Tablet, Lyophilized Bacterial Lysates 50mg Tablet
Glycine 43 mg tablet, Haemophilus Influenzae Type B (Hib) 6 giga organismer tablet, Klebsiella Ozaenae 6 giga organismer tablet, Klebsiella Pneumoniae 6 giga organismer tablet, Neisseria Catarrhalis 6 giga organismer tablet, Staphylococcus Aureus 6 giga organismer tablet, Streptococcus Pneumoniae 6 giga organismer tablet , Streptococcus Pyogenes 6 giga organismer tablet, Streptococcus Oralis 6 giga organismer tablet, Lyofiliserede Bakterielle Lysater 50 mg tablet
Glycine 43mg Tablet, Haemophilus Influenzae Type B (Hib) 6 Giga Organisms Tablet, Klebsiella Ozaenae 6 Giga Organisms Tablet, Klebsiella Pneumoniae 6 Giga Organisms Tablet, Neisseria Catarrhalis 6 Giga Organisms Tablet, Staphylococcus Aureus 6 Giga Organisms Tablet, Streptococcus Pneumoniae 6 Giga Organisms Tablet, Streptococcus Pyogenes 6 Giga Organisms Tablet, Streptococcus Oralis 6 Giga Organisms Tablet, Lyophilized Bacterial Lysates 50mg Tablet
Lyofiliseret, standardiseret bakterieekstrakt 3,5 mg kapsel
Lyophilised, Standardised Bacterial Extract 3.5mg Capsule
Proteoglycaner af Klebsiella Pneumoniae 1,125 mg pose, Ribosomer af Haemophilus Influenzae 5 enheder pose, Ribosomer af Streptococcus Pneumoniae 30 enheder pose, Ribosomale Fraktioner af Klebsiella Pneumoniae 35 enheder pose, Ribosomer fra Streptococcus Pyogenes Gruppe A 30 enheder pose
Proteoglycanes Of Klebsiella Pneumoniae 1.125mg Sachet, Ribosomes Of Haemophilus Influenzae 5 Units Sachet, Ribosomes Of Streptococcus Pneumoniae 30 Units Sachet, Ribosomal Fractions Of Klebsiella Pneumoniae 35 Units Sachet, Ribosomes From Streptococcus Pyogenes Group A 30 Units Sachet
Broncho-Vaxom Lyofiliserede bakterielle lysater 3,5 mg pose
Broncho-Vaxom Lyophilized Bacterial Lysates 3.5mg Sachet
Broncho-Vaxom Lyofiliserede bakterielle lysater 7 mg kapsel
Broncho-Vaxom Lyophilized Bacterial Lysates 7mg Capsule
Haemophilus Influenzae 6 giga celler tablet, Klebsiella Ozaenae 6 giga celler tablet, Klebsiella Pneumoniae 6 giga celler tablet, Neisseria Catarrhalis 6 giga celler tablet, Staphylococcus Aureus 6 giga celler tablet, Streptococcus Pneumoniae 6 giga celler tablet, Streptococcus Pyogenes 6 giga celler tablet, Streptococcus Oralis 6 giga celler tablet
Haemophilus Influenzae 6 Giga Cells Tablet, Klebsiella Ozaenae 6 Giga Cells Tablet, Klebsiella Pneumoniae 6 GigaCells Tablet, Neisseria Catarrhalis 6 Giga Cells Tablet, Staphylococcus Aureus 6 Giga Cells Tablet, Streptococcus Pneumoniae 6 Giga Cells Tablet, Streptococcus Pyogenes 6 Giga Cells Tablet, Streptococcus Oralis 6GigaCells Tablet